All filters
Slidesets
Pharmacokinetic-Pharmacodynamic Analysis in TB Drug Development and the Role of the WHO - Ernesto Jaramillo
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
PK-PD of Isoniazid Given at Different Doses Among Patients with MDR-TB with INH Resistance Mediated by inhA Mutations: Modeling Results from ACTG A5312 - Kamunkhwala Gausi
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis - Charles Peloquin
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Drug Effect of Clofazimine on Persistent Mycobacteria Explain an Unexpected Increase of Bacterial Load in Patients - Alan Faraj
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Levofloxacin Target Attainment Analysis in MDR-TB Patients: Time is Ripe for Proactive TDM - Mathieu Bolhuis
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Slidesets
Abstract: A pharmacometric framework for dose individualisation of sunitinib in GIST (#O2) | Maddalena Centanni
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Rationale for selecting combinations with immunotherapy | Howard Gurney, MBBS, FRACP
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Immunotherapy of prostate cancer and urothelial cancer. Future directions | Winald Gerritsen, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS | Michelle Rudek, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs) | Ron Mathijssen, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Drug-drug interaction management with DDI-Predictor | Michel Tod, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: Food intervention to make therapy with pazopanib more patient friendly and affordable (#06) | Floor Lubberman
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches (#05) | Stefanie Krens
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: A Pharmacokinetic-Pharmacodynamic binding model of Bevacizumab to VEGF as a tool to optimize treatment (#07) | Apostolos Papachristos
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft models (#O8)
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: Translation from mouse to human of pharmacokinetic-pharmacodynamic modelling of biomarker response – learnings from the AstraZeneca Oncology portfolio (#10) | Rhys Jones
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: The relationship between busulphan AUC and the incidence of sinusoidal obstruction syndrome in haematopoietic stem cell transplants (#O9) | Parth Upadhyay
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: Correlation between nivolumab exposure and treatment outcome in NSCLC (#O1) | Sander Bins
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Targeted agents and monoclonal antibodies | Joseph Ciccolini, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Cytotoxic agents | Markus Jörger, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018